Key points are not available for this paper at this time.
With the introduction of the PSA test, screening for prostate cancer has become wide-spread practice. However, no evidence exists that screening for prostate cancer leads to a disease-specific mortality reduction. To provide evidence showing or excluding this mortality reduction, a large randomized trial was conducted in 1994, the European Randomized Study of Screening for Prostate Cancer (ERSPC). A total of eight centres from Europe participated in this trial and so far a total of 267,994 men are randomized: 126,219 in the screening arm, 141,775 in the control arm. No final endpoint has been reached yet and the ERSPC is still ongoing. However, up to now the ERSPC has provided much data on screening tests and protocols, biopsy outcome and predictors and early detection of prostate cancer.
Schröder et al. (Sat,) studied this question.